Physician profile
Jesse E Morriss
NPI 1063481273
$7,668.73
in general payments reported to CMS, 2019-2025
42 companies · $892 in 2025
The $892 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,281 · 2020: $982 · 2021: $1,390 · 2022: $1,588 · 2023: $737 · 2024: $798 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,427.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $780.53 | 2019-2024 | Spravato, Xarelto |
| Abbvie INC. | $753.16 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $686.51 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $622.10 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $582.30 | 2019-2024 | Ozempic |
| Pfizer INC. | $421.06 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $385.18 | 2020-2024 | Trintellix |
| Amarin Pharma, INC. | $384.47 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.76 | 2019-2022 | |
| Lilly USA, LLC | $258.62 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $230.44 | 2019-2025 | Evenity, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $221.56 | 2023-2025 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $201.66 | 2019-2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $165.19 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.82 | 2022-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.55 | 2022-2025 | Ofev, Jardiance |
| Corcept Therapeutics | $137.39 | 2022-2025 | Korlym |
| Nevro Corp. | $134.94 | 2021-2024 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $133.73 | 2022 | |
| Novartis Pharmaceuticals Corporation | $115.22 | 2019-2022 | |
| Corium, LLC | $113.01 | 2022-2023 | Azstarys |
| Allergan, INC. | $112.19 | 2019-2020 | |
| Abbott Laboratories | $109.50 | 2021-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $82.73 | 2019-2025 | |
| Shire North American Group INC | $63.12 | 2019 | |
| Merck Sharp & Dohme LLC | $49.01 | 2022-2023 | Dificid |
| Dexcom, INC. | $44.13 | 2024-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $40.36 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $36.62 | 2024 | Voquezna |
| Lundbeck LLC | $33.18 | 2024 | Rexulti |
| Exact Sciences Corporation | $26.99 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Horizon Therapeutics Plc | $25.51 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $25.32 | 2019 | |
| Xeris Pharmaceuticals, INC. | $23.47 | 2023 | Gvoke Hypopen |
| Ucb, INC. | $22.53 | 2022 | |
| Inspire Medical Systems, INC. | $18.71 | 2025 | Inspire |
| Eisai INC. | $16.03 | 2022 | |
| Esperion Therapeutics, INC. | $13.93 | 2025 | Nexletol |
| Sun Pharmaceutical Industries INC. | $12.75 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.66 | 2022 | |
| Acadia Pharmaceuticals INC | $11.81 | 2019 | |
| Inogen, INC. | $7.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Morriss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.